Thymosin Alpha-1
Tα1, TA-1, Zadaxin
Mechanism
Thymus-derived peptide that modulates T-cell maturation, enhances dendritic cell function, and upregulates MHC class I expression. Used clinically for hepatitis B/C and cancer immunotherapy.
Benefits
- āT-cell immune reconstitution
- āAntiviral activity
- āAnti-tumor immune support
- āImmune modulation in autoimmunity
- āImproved response to vaccines
Dosing
Clinical dose: 1.6mg (1600mcg) 2x/week. Research: 100ā200mcg daily.
Reconstitution
10mg + 3mL BAC = 3,333mcg/mL.
Cycle Length
Acute protocols: 4ā6 weeks 2x/week. Ongoing: 2x/week indefinitely.
Timing
SubQ any time. Twice weekly (e.g., Mon/Thu).
Stacks Well With
LL-37, BPC-157, VIP
Cautions
Well-tolerated. Avoid with organ transplant (may enhance rejection of graft).